Compatibility of Different Formulations in TrichoConcept™ Vehicles for Hair Treatments

Abstract

The wide variety of potential pathogeneses for alopecia and the wide variety of active pharmaceutical ingredients (APIs) to treat and manage those pathogeneses highlight the importance of the development of stable and effective topical treatments. Topical options for alopecia on the market remain limited and oral products may result in unwanted systemic adverse effects. This study is meant to fill the gap by determining compatibility in terms of beyond‐use date (BUD) of APIs with theoretical or demonstrated benefits for topical use for alopecia. The compatibility of seven formulations was tested: F1 = clobetasol 0.05% in TrichoWash™; F2 = ketoconazole 2% in TrichoWash™; F3 = spironolactone 1% in TrichoWash™; F4 = latanoprost 0.1% in TrichoCream™; F5 = pyridoxine HCl 0.5%, vitamin A acetate 1%, and vitamin E succinate 12.1 IU in TrichoCond™; F6 = Caffeine 2%, menthol 1%, and pyridoxine HCl 0.5% in TrichoWash™; F7 = Latanoprost 0.1%, minoxidil 5%, and finasteride 0.25% in TrichoSol™. All formulations presented a BUD of 6 months, except for F4 and F7, which showed compatibility for 3 months. This validates the compatibility of the APIs with the Trichotech™ vehicles, and that they are highly convenient for compounding pharmacies.